



conditions.⁷ The trans disposition of the acetoxy and methyl groups attached to C-2 and C-3 of photoproduct 5 was assigned by its ¹H NMR spectrum ($J_{2-H-3-H} = 1.98$ Hz). Treatment of naphthofurandione 5 with potassium *tert*-butoxide in THF at 0 °C resulted in the elimination of acetic acid, giving maturinone (6) in 52% yield.

The initial products in the present photoaddition are furanohydroquinones; 4,9-diacetoxy-2,3-dihydro-2,2,4,4-tetramethylnaphtho[2,3-*b*]furan (7)⁹ can be isolated in 36% yield together with 2,2,4,4-tetramethylnaphtho[2,3-*b*]furan (3c) (18%) when the crude products from the photoaddition between hydroxynaphthoquinone 1 (1 mmol) and 2,3-dimethyl-2-butene (10 mmol) in acetone (40 mL) are treated with acetic anhydride (1 mL) and pyridine (1 mL) under nitrogen for 2 h at 60 °C (eq 3).



The probable gross reaction pathway of the addition leading to the hydroquinones is outlined in eq 4. A comparison of the electronic absorption spectrum of 2-hydroxy-1,4-naphthoquinone (1) with that of 2-methoxy-1,4-naphthoquinone¹⁰ indicates that no orthoquinone form of 2-hydroxynaphthoquinone exists in solution. The initial events in this photochemical addition can be explained within the framework of an accepted model of [2 + 2]_r photochemical additions.¹¹ Irradiation of 1 in acetone or benzene generates tautomeric excited triplets (A) and (A'), which react with an alkene through a triplet exciplex to give biradical (B_i) and/or (B_i'). In view of the strong electron-accepting character of naphthoquinone,¹² it seems likely that the exciplex or these biradical intermediates have appreciable polar character or are ionic intermediates (B_i) and (B_i') generated by electron transfer. The regioselectivity found in the present addition is a clear in-



dication of the involvement of a more stabilized polar biradical or ionic intermediate, such as B_i and B_i', in the formation of dihydronaphtho[2,3-*b*]furan-4,9-diones. Intramolecular cyclization of the intermediate gives hydroquinones (C) and (C'). In contrast to the photoaddition¹³ of 1,4-naphthoquinone with alkenes, no trace of [2 + 2]_r cycloadducts were observed in the present photoadditions. 2,3-Dihydronaphthofuran-4,9-dione is then formed by air oxidation of the hydroquinone during the workup and isolation procedures.

Additional mechanistic and synthetic aspects of the present *formal* [2 + 3] photoaddition are presently under investigation and will be reported in a forthcoming full paper.

Supplementary Material Available: Experimental details for the synthesis of 3a-g and maturinone (6) and for isolation of diacetoxyfuranohydroquinone 7 from the photoaddition between hydroxynaphthoquinone 1 and 2,3-dimethyl-2-butene (4 pages). Ordering information is given on any current masthead page.

(10) Singh, I.; Ogata, R. T.; Moore, R. E.; Chang, C. W. J.; Scheuer, P. J. *Tetrahedron* 1968, 24, 6053.

(11) For reviews, see: (a) Baldwin, S. W. In *Organic Photochemistry*; Padwa, A., Ed.; Marcel Dekker: New York, 1981; Vol. 5, pp 123-225. (b) Weedon, A. C. In *Synthetic Organic Photochemistry*; Horspool, W. M., Ed.; Plenum: New York, 1980; pp 91-143.

(12) E.g.: Rao, P. S. *Nature* 1973, 243, 344. Rao, P. S.; Hayon, E. J. *Am. Chem. Soc.* 1974, 96, 1287.

(13) (a) Otsuki, T. *Bull. Chem. Soc. Jpn.* 1976, 49, 2596. (b) Maruyama, K.; Narita, N. *Ibid.* 1980, 53, 757. (c) Ochiai, M.; Arimoto, M.; Fujita, E. *J. Chem. Soc., Chem. Commun.* 1981, 460. (d) Liu, H. J.; Chan, W. H. *Can. J. Chem.* 1980, 58, 2196. (e) Maruyama, K.; Otsuki, T.; Tai, S. *J. Org. Chem.* 1985, 50, 52.

Highly Efficient Synthesis of 13-Dehydroprostaglandins by 1,4-Addition Reaction of Alkynyl ω Side-Chain Unit onto Cyclopentenone Framework

Toshiharu Yoshino, Sentaro Okamoto, and Fumie Sato*

Department of Biomolecular Engineering, Tokyo Institute of Technology, Meguro, Tokyo 152, Japan


Received March 19, 1991

Summary: Optically active 2-((diethylamino)methyl)-4-siloxy-2-cyclopentenone (2) reacts with a diethyl(3-(*tert*-butyldimethylsiloxy)-1-alkynyl)aluminum compound via 1,4-addition pathway to afford the enone 5, useful intermediate for synthesis of PGs via two-component coupling process, in excellent yield, thus making it easy to synthesize 13-dehydro-PGs.

The synthesis of analogues of prostaglandins (PGs) has attracted much interest for use in biological and clinical

investigations.¹ A number of analogues in which the double bond at C-13 (PG numbering) has been replaced by triple bond have been prepared and some of which have deserved particular attention as promising therapeutic agents.²

(1) Bindra, J. S.; Bindra, R. *Prostaglandin Synthesis*; Academic: New York, 1977. Mitra, A. *Synthesis of Prostaglandins*; Wiley-Interscience: New York, 1977. *New Synthetic Routes to Prostaglandins and Thromboxanes*; Roberts, S. M., Scheinmann, F., Eds.; Academic: New York, 1982. Noyori, R.; Suzuki, M. *Angew. Chem., Int. Ed. Engl.* 1984, 23, 847.


Table I. Yields, Characteristic NMR Data, and $[\alpha]_D$ Values of 5 and 6


4 ^a	R	isolated yield, ^b %		¹ H NMR coupling constants $J_{11,12}$ (Hz)		¹³ C NMR chemical shifts of C-11 and C-12 ^d (ppm)		$[\alpha]_D^{25}$ (c, CHCl ₃), ^e deg, of 5
		5	6	5	6	5: C-11/C-12	6: C-11/C-12	
4a		82	14	6.8 ^f	4.0	73.3/43.6	69.5/42.1	-54.6 (c 1.03)
4b		90	4	6.8	4.2	73.3/43.6	69.6/42.3	-50.0 (c 1.20)
4c		83	8	6.8	4.8	73.3/43.5	69.6/42.3	-51.2 (c 1.38)
4d		50	19	7.0 ^f	4.0	73.5/43.8	69.8/42.4	- ^g
4e		54	45	6.8	4.0	73.2/43.5	69.6/42.1	-30.3 (c 1.12)
4f		59	39	7.2 ^f	3.8 ^f	73.7/43.8	69.9/42.5	-45.1 (c 1.50)

^a Prepared from the corresponding alkyne by sequential treatment with *n*-BuLi (1.66 M, hexane) and 1.2 equiv of Et₂AlCl (1.0 M, hexane) in benzene. The enantiomerically pure alkynes used for preparation of 4a, 4b, and 4c were synthesized according to the procedure reported by us (ref 15). ^b The enone 2 was treated with 1.3 equiv of 4, and the yield is based on 2. *R_f* values (analytical TLC (E. Merck, silica gel 60 F₂₅₄ plates), hexane/Et₂O = 6/1) are as follows: 5a/6a = 0.60/0.38, 5b/6b = 0.60/0.34, 5c/6c = 0.60/0.38, 5d/6d = 0.58/0.40, 5e/6e = 0.50/0.26, 5f/6f = 0.53/0.37. ^c Unless otherwise indicated, on decoupling of C-10 protons, the signal of C-11 proton was observed as a doublet with the coupling constant given. Full data of ¹H NMR of 5 and 6 are available as supplementary material. ^d Full data of ¹³C NMR of 5 and 6 are available as supplementary material. ^e $[\alpha]_D$ values of 5d and 6 were not determined. ^f On decoupling of C-15 proton, the signal of C-12 proton was observed as a doublet with the coupling constant given. ^g The signal of C-12 proton was observed as a doublet-triplet: 5d ($J_{12,15} = 2.4$ Hz), 5f ($J_{12,15} = 2.2$ Hz), 6f ($J_{12,15} = 2.2$ Hz).

A conjugate addition of organometallic derivatives to cyclopentenones which is classified into two- and three-component coupling process provides an attractive, convergent approach to PGs. This method has been widely applied to the synthesis of naturally occurring PGs and pharmaceutically important PG analogues.^{1,3} The synthesis of 13-dehydro-PGs by introduction of alkynyl moiety into cyclopentenones, however, remains unsolved. For example, 2-(6-carbomethoxyhexyl)-4-hydroxy-2-cyclopentenone (1) reacted with tris(3-(tetrahydropyranyl)-1-octynyl)aluminum to give 1,4-addition product; however, the addition occurred at the same face of C-11 hydroxyl group giving only undesired 12 α -isomer (eq 1). While protection of the hydroxyl group of 1 by a tetra-

hydropyranyl group prevented reaction with the aluminum reagent.⁴



Recently we have directed our efforts to make the two-component coupling synthesis of PGs as an industrially viable process by developing efficient, practical methods to prepare the required key intermediates such as cyclopentenones⁵ and ω side-chain units.⁶ Thus, we have succeeded in synthesizing 2-((diethylamino)methyl)-4-siloxy-2-cyclopentenone (2)⁷ in 50% overall yield starting from readily available (2*R*,3*S*)-1,2-epoxypent-4-en-3-ol and have shown that 2 thus prepared reacts with organocopper compounds derived from an ω side chain to

(2) (a) Gandolfi, C.; Pellegata, R.; Dradi, E.; Forgiione, A.; Pella, E. *Farmaco Ed. Sci.* 1976, 31, 763. (b) Gandolfi, C.; Dorio, G.; Gaio, P. *Ibid.* 1972, 27, 1125. (c) Franceschini, J.; Mizzotti, B.; Ceserani, R.; Mandelli, V.; Usardi, M. M. *Pharmacol. Res. Commun.* 1977, 9, 899. (d) Impicciatore, M.; Usardi, M. M.; Bertaccini, G. *Ibid.* 1976, 8, 187. (e) Jarabak, J.; Brathwaite, S. *Arch. Biochem. Biophys.* 1976, 177, 245. (f) O-Yang, C.; Fried, J. *Tetrahedron Lett.* 1983, 24, 2533. (g) Fried, J.; Barton, J. *Proc. Natl. Acad. Sci. U.S.A.* 1977, 74, 2199. (h) Garmelo, A.; Ryszard, J. G. *Pharmacol. Res. Commun.* 1978, 10(10), 885. (i) Fried, J.; Mitra, D. K.; Nagarajan, M.; Mehrotra, M. M. *J. Med. Chem.* 1980, 23, 234. (j) Skuballa, W.; Vorbrüggen, H. *Adv. PG TX LT Res.* 1983, 11, 299. (k) Skuballa, W.; Vorbrüggen, H. *Ibid.* 1985, 15, 271. (l) Skuballa, W.; Schillinger, E.; Stürzebecher, C.-St.; Vorbrüggen, H. *J. Med. Chem.* 1986, 29, 313.

(3) Recent synthesis via conjugate addition approach, see: Suzuki, M.; Yanagisawa, A.; Noyori, R. *J. Am. Chem. Soc.* 1988, 110, 4718. Johnson, C. R.; Penning, T. D. *Ibid.* 1988, 110, 4726. Daniahefsky, S. J.; Cabal, M. P.; Chow, K. *Ibid.* 1989, 111, 3456. Morita, Y.; Suzuki, M.; Noyori, R. *J. Org. Chem.* 1989, 54, 1785. Lipshutz, B. H.; Ellsworth, E. L. *J. Am. Chem. Soc.* 1990, 112, 7440. Babiak, K. A.; Behling, J. R.; Dygos, J. H.; McLaughlin, K. T.; Ng, J. S.; Kalish, V. J.; Kramer, S. W.; Shone, R. L. *Ibid.* 1990, 112, 7441 and see also ref 5.


(4) Pappo, R.; Collins, P. W. *Tetrahedron Lett.* 1972, 2627. Collins, P. W.; Dajani, E. Z.; Bruhn, M. S.; Brown, C. H.; Palmer, J. R.; Pappo, R. *Ibid.* 1975, 4217.

(5) (a) Okamoto, S.; Kobayashi, Y.; Kato, H.; Hori, K.; Takahashi, T.; Tsuji, J.; Sato, F. *J. Org. Chem.* 1988, 53, 5590. (b) Okamoto, S.; Kobayashi, Y.; Sato, F. *Tetrahedron Lett.* 1989, 30, 4379. (c) Tsujiyama, H.; Ono, N.; Yoshino, T.; Okamoto, S.; Sato, F. *Ibid.* 1990, 31, 4481.

(6) Okamoto, S.; Shimazaki, T.; Kobayashi, Y.; Sato, F. *Tetrahedron Lett.* 1987, 28, 2033. Kitano, Y.; Matsumoto, T.; Okamoto, S.; Shimazaki, T.; Kobayashi, Y.; Sato, F. *Chem. Lett.* 1987, 1523. Kitano, Y.; Matsumoto, T.; Wakasa, T.; Okamoto, S.; Shimazaki, T.; Kobayashi, Y.; Sato, F.; Miyaji, K.; Arai, K. *Tetrahedron Lett.* 1987, 28, 6351.

(7) The compound 2 is now commercially available from Nissan Chemical Industries, Ltd. (Japan).

afford **3** in excellent yields, which in turn reacts with an α side chain as reported by Stork and his co-workers to afford PGs (eq 2).⁵



We expected that the amino group present in **2** would activate an alkynylaluminum compound by coordination, thus making it possible to introduce an alkynyl moiety into **2** at the opposite face of the C-11 hydroxyl group via a 1,4-addition pathway. Herein reported is the successful realization of this idea which undoubtedly simplifies the synthesis of 13-dehydro-PGs.⁸

When **2** was reacted with diethyl(3-(*tert*-butyldimethylsilyloxy)-1-octynyl)aluminum (**4a**) in benzene at room temperature, 1,4-addition did occur to afford, after hydrolysis, a mixture of two diastereoisomers.^{9,10} These were readily separated by column chromatography (SiO₂) to give **5a** having the desired 12 β configuration and **6a** (12 α isomer) in 82% and 14% yields, respectively. The assignment of the configuration of the two isomers follows from the ¹H NMR coupling constant between the two protons at C-11 and C-12 (PG numbering, *J* = 4.0 Hz for cis and *J* = 6.8 Hz for trans) and ¹³C NMR chemical shifts of C-11 and C-12, since the resonances for these carbons in **6** (cis configuration) are always upfield of those in **5** (trans configuration).¹¹ Table I shows the yields, characteristic ¹H and ¹³C NMR data, and $[\alpha]_D$ values of the products obtained by the reaction of **2** with various diethylalkynylaluminum compounds **4a-f**. As can be seen from the table, in every case, the 12 β -isomer **5** was major; however, somewhat diminished diastereoselectivities were observed with the decrease of the steric bulk of alkynyl moiety.


(8) Previous synthesis of 13-dehydro-PGs: via epoxide ring opening by alkynyl anion; Fried, J.; Sih, J. C. *Tetrahedron Lett.* 1973, 3899. Fried, J.; Lin, C. H. *J. Med. Chem.* 1973, 16, 429. Fried, J.; Lee, M.-S.; Gaede, B.; Sih, J. C.; Yoshikawa, Y.; McCracken, J. A. *Adv. Prostaglandin Thromboxane Res.* 1976, 1, 183. Ohno, K.; Nishiyama, H.; Nagase, H.; Matsumoto, K.; Ishikawa, M. *Tetrahedron Lett.* 1990, 31, 4489. See also ref 2g and 2j. Via dehydrohalogenation of 14-halo-PG intermediate; Smith, H. W.; Mich, K. U.S. Patent 4,029,681 (1977). Takahashi, A.; Shibasaki, M. *J. Org. Chem.* 1988, 53, 1227. See also ref 2b and 2i.

(9) The nucleophilic S_N2' addition of organometallic reagents to allylamine derivatives has been reported: Doomes, E.; Clarke, U.; Neitzel, J. J. *J. Org. Chem.* 1987, 52, 1540. Hutchinson, D. K.; Fuchs, P. L. *J. Am. Chem. Soc.* 1985, 107, 6137. Hutchinson, D. K.; Fuchs, P. L. *J. Am. Chem. Soc.* 1987, 109, 4755.

(10) ¹H and ¹³C NMR studies of the reaction mixture (before hydrolysis) demonstrated the formation of the aluminum enolate.

(11) For 2-alkynylcyclopent-3-en-1-ol: Briggs, A. J.; Walker, K. A. M. *J. Org. Chem.* 1990, 55, 2962. For 2-methylcyclopentanol: Christl, M.; Reich, H. J.; Roberts, J. D. *J. Am. Chem. Soc.* 1971, 93, 3463. For prostaglandins: Cooper, G. F.; Fried, J. *Proc. Natl. Acad. Sci. U.S.A.* 1973, 70, 1579. Mizeak, S. A.; Slomp, G. *Prostaglandins* 1975, 10, 807. Arroniz, C. E.; Gallina, J.; Martinez, E.; Muchowski, J. M.; Velarde, E.; Rooks, W. H. *Ibid.* 1978, 16, 47.

With the compound **5a** in hand, we then carried out the synthesis of the methyl ester of 13-dehydro-PGE₁ and -PGF₁ by 1,4-addition of α side-chain unit onto it (eq 3).



Thus the reaction of **5a** with organocopper reagent **7**, prepared from the corresponding organozinc reagent and CuCN·2LiCl, in the presence of Me₃SiCl provided, after hydrolysis, disilyl ether of 13-dehydro-PGE₁ methyl ester (**8**) ($[\alpha]_D^{25} -47.3^\circ$ (*c* 1.96, CHCl₃) in 78% yield.^{5c} Protodesilylation of **8** with (HF)_n-pyridine in acetonitrile afforded 13-dehydro-PGE₁ methyl ester (**9**) ($[\alpha]_D^{24} -43.8^\circ$ (*c* 0.484, CHCl₃), mp 46.0–46.5 °C (lit.¹² mp 46 °C)) in 85% yield. While the reduction of **8** with L-Selectride (Aldrich) followed by protodesilylation (aqueous HF, CH₃CN) gave 13-dehydro-PGF₁ methyl ester (**10**) ($[\alpha]_D^{22} +21.7^\circ$ (*c* 0.60, CHCl₃) in 58% overall yield from **8**, mp 68.0–68.5 °C (lit.¹² mp 68 °C)). The spectroscopic data (¹H NMR, IR, and MS) of **9** and **10** are in good agreement with the literature.¹²

Since PG analogues having 17-methyl-15-hydroxy¹³ and 15-dehydroxy-16-methyl-16-hydroxy¹⁴ moiety as an ω side chain have been accepted as promising therapeutic agents, the synthesis of 13-dehydro version of these PGs using the enones **5c** and **5d** is in progress in our laboratory.

Supplementary Material Available: Experimental procedure for preparation of **5** and **6** and spectroscopic data (IR and ¹H and ¹³C NMR) of **5a-f**, **6a-f**, **8-10**, and the disilyl ether of **10** (6 pages). Ordering information is given on any current masthead page.

(12) Smith, H. W.; Mich, K. U.S. Patent 4,058,564 (1977).

(13) (a) Tauboi, T.; Fujitani, B.; Maeda, J.; Yoshida, K.; Shimizu, M.; Kawasaki, A.; Okegawa, T.; Tsuboshima, M. *Thrombosis Res.* 1980, 20, 573. (b) Tauboi, T.; Hatano, N.; Nakatsuji, K.; Fujitani, B.; Yoshida, K.; Shimizu, M.; Kawasaki, A.; Sakata, M.; Tsuboshima, M. *Adv. Prostaglandin Thromboxane Res.* 1980, 6, 347. (c) *Pharmaprospect*, Vol. 7, Prostaglandin (H4B); Sochynsky, R., Hardcastle, J., Eds.; V&O Publications Ltd.: Surrey, 1986.

(14) Larsen, K. R.; Jensen, N. F.; Davis, E. K.; Jensen, J. C.; Moody, F. G. *Prostaglandins* 1981, 21 (Suppl), 119. Collins, P. W.; Dajani, E. Z.; Pappo, R.; Gasielki, A. F.; Bianchi, R. G.; Woods, E. M. *J. Med. Chem.* 1983, 26, 786. Kaymakalan, H.; Wilson, D. E.; Khader, M.; Ramsamooj, E.; Adams, A. *Clin. Res.* 1981, 29, 758A. Wilson, D. E.; Levendglu, H.; Adams, A.; Ramsamooj, E. *Prostaglandins* 1984, 28, 5. Collins, P. W. *J. Med. Chem.* 1986, 29, 437. See also ref 13c.

(15) Ito, T.; Okamoto, S.; Sato, F. *Tetrahedron Lett.* 1989, 30, 7083.

A Novel Method for the Synthesis of Spiroketal Systems. Synthesis of the Pheromones of the Common Wasp and the Olive Fruit Fly

Philip DeShong* and Philip J. Rybczynski

Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742

Received March 8, 1991

Summary: Total syntheses of the pheromones of the common wasp and the olive fruit fly were accomplished by a strategy in which the key transformation involved the

cleavage of tetrahydrofuran with (*tert*-butyldimethylsilyl)manganese pentacarbonyl followed by sequential insertion of ethyl acrylate.